|Bieżący numer Archiwum O czasopiśmie Suplementy Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac||
Determination of the value of glycated hemoglobin HbA1c and fructosamine in assessing the risk of perioperative complications after cardiac surgery in patients with type 2 diabetes
Anetta M. Kowalczuk-Wieteska, Marta Wróbel, Dominika Rokicka, Aleksandra Szymborska-Kajanek, Jerzy Foremny, Paweł Nadziakiewicz, Marian Zembala, Krzysztof Strojek
Kardiochirurgia i Torakochirurgia Polska 2016; 13 (4): 305-308
- Determination of the value.pdf [0.17 MB]
IntroductionDiabetes, in particular type 2, is a condition which significantly increases the risk of development and progression of atherosclerosis [1, 2]. It is estimated that 60% of patients hospitalized with coronary artery disease have varying degrees of impaired glucose tolerance [3, 4]. Metabolic disorders in diabetes can cause coagulation disorders, hypertension, dyslipidemia, and synthesis of free radicals . They can worsen the perioperative course and prognosis in patients undergoing cardiac surgery . According to the recommendations of the Polish Association of Diabetes, metabolic preparation of the patient for surgery includes normalization of blood glucose . The measure of glycemic control is the determination of the concentration of glycated hemoglobin (HbA1c). It is assumed that the patient eligible for surgery should have a balanced glucose level of HbA1c < 7%. Remember, however, it should be that the concentration of glycated hemoglobin reflects the alignment within 3 months preceding the mark . In a situation where the patient is eligible for the procedure, and does not meet the metabolic control (HbA1c < 7%), it is necessary to intensify hypoglycemic therapy that will lead to the normalization of the blood glucose profile. There remains the situation where the patient has a normal blood glucose daily profile and still maintains elevated glycosylated hemoglobin, which according to the recommendations disqualifies a patient from the planned surgery.
The process of non-enzymatic glycation, which is the product of glycated hemoglobin, is a reaction that includes all proteins. It consists of a combination of a glucose molecule with the free amino group of the polypeptide chain . The protein albumin is subject to glycation and as a result of this process produces fructosamine, a somewhat forgotten parameter that determines the glycemic control. Given the life of albumin, the concentration of fructosamine determines glycemic control during the 3–4 weeks prior to the measurement . It seems, therefore, that determination of fructosamine can be a useful study determining the metabolic alignment, especially the situation of hypoglycemic treatment and the need to verify the information factors.
AimGlycemic control is necessary in patients with diabetes subjected to cardiac surgery. Evaluation of alignment is based on the determination of the percentage of glycated hemoglobin A1c, which reflects the alignment of the preceding 3 months. The open issue is whether the determination of the concentration of fructosamine reflecting alignment in the previous 3 weeks will be a comparable parameter. The aim of the study is to evaluate metabolic control by the concentration of fructosamine and the percentage of HbA1c with respect to the occurrence of postoperative complications in diabetic patients undergoing coronary artery bypass grafting.
Material and methodsWe analyzed the results of off-pump coronary artery bypass (OPCAB) and coronary artery bypass graft (CABG) procedures performed in 105 patients with type 2 diabetes in 2014–2015. The mean age was 65.7 ±7.3.
Diabetes duration was 9.2 ±2.3 years. In all subjects, the concentration of fructosamine and HbA1c was designated. The analysis included postoperative complications. We analyzed the following complications: delirium, stroke, prolonged respiratory therapy > 24 h, slow wound healing, visceral ischaemia, death.
Statistical analysisThe results were statistically analyzed. Average value ± SD and events of interest were calculated. Comparisons between selected groups were made using the χ2 test with Yates correction for continuity.
ResultsMean HbA1c level in the study group was 7.23 ±1.2% and fructosamine concentration was 261 ±43.8 mmol/l. Figure 1 shows the correlation between the percentage of glycated hemoglobin A1c and fructosamine. There was a significant correlation between these parameters (r = 0.597, p < 0.001).
In the total study group of 105 patients perioperative complications occurred in 9 (8.5%) patients. There was a higher, though not significantly, value of the tested parameters of glycemic control in diabetic patients with perioperative complications compared to patients with an uncomplicated course (Tab. I).
Next we calculated percentages of patients who experienced perioperative complications depending on the HbA1c and the corresponding concentration of fructosamine. As the cut-off point for HbA1c we adopted HbA1c 7% – a reference value for optimal glycemic control during the perioperative period . Complications occurred in 4 (3.8%) patients with HbA1c < 7%, and 5 (4.8%) patients with HbA1c ≥ 7% (n.s.). For fructosamine the figures were 6 (5.7%) patients with a concentration of < 285 μmol/l and 3 (2.9%) at a concentration ≥ 285 μmol/l (n.s.).
DiscussionIn the present study, we found that the percentage of HbA1c as much as the concentration of fructosamine defines the risk of perioperative complications in patients undergoing cardiac surgery. The analysis includes only those complications that are potentially associated with the environment hyperglycemia .
First, an analysis of the correlation between HbA1c and fructosamine was performed. There was a high, statistically significant correlation, indicating that both of these parameters to a comparable extent describe the metabolic control of patients.
Subsequently we rated interdependent incidence of perioperative complications and concentrations of the test parameters. Noteworthy is the fact that the incidence of complications in the study group is small, not different from their appearance in our center . This is due to the fact that one of the elements taken into account to qualify for the surgery is the degree of metabolic control.
Glycemic control plays an important role in the prognosis after cardiac surgery [13, 14]. Zerr et al. analyzing a database including 8910 patients, including 1585 patients with diabetes, found that the implementation of procedures of treatment, enabling one to obtain blood glucose during the perioperative period of less than 200 mg%, reduces the incidence of deep wound infection from 2.4% to 1.5% (p < 0.02). We noted a similar percentage of deep wound infection in our study, where one of the elements of the qualification is to assess glycemic control. In the present analysis, the percentage of patients with delayed wound healing was 2.17% in the group with HbA1c < 7%, and 1.69.% for HbA1c ≥ 7% and the corresponding concentration of fructosamine.
ConclusionsThe HbA1c and fructosamine levels to a similar extent define the risk of perioperative complications in patients undergoing cardiac surgery. Given the dynamics of temporal changes in the concentrations of these substances in the event of a rapid normalization of blood glucose, one should consider including designation of fructosamine panel tests performed before surgery, especially in patients in whom there is a need to quickly compensate for elevated blood glucose.
DisclosureAuthors report no conflict of interest.
References1. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: a meta-analysis of 37 prospective cohort studies. BMJ 2006; 332: 73-78.
2. Sloan FA, Bethel MA, Ruiz D Jr, Shea AM, Feinglos MN. The growing burden of diabetes mellitus in the US elderly population. Arch Intern Med 2008; 168: 192-199.
3. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendíc S, Rydén L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359: 2140-44.
4. Wlodarczyk A, Strojek K. Glucose intolerance, insulin resistance and metabolic syndrome in patients with stable angina pectoris. Obesity Predicts coronary atherosclerosis and dysglycemia. Pol Arch Med Wewn 2008; 118: 719-26.
5. Moreno, PR, Fuster V. New aspects in the pathogenesis of diabetic stherothrombosis. J Am Coll Cardiol 2004; 44: 2293-2300.
6. Thourani VH, Weintraub WS, Stein B, Gebhart SS, Craver JM, Jones EL, Guyton RA. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg 1999; 67: 1045-1052.
7. Polish Diabetes Association. Clinical Recommendations for the management of patients with diabetes in 2016. Clin Diabetol 2016; 5 (Suppl A).
8. Lanoe R, Soria J, Thibult N, Soria C, Eschwege E, Tchobroutsky G. Glycosylated hemoglobin concentrations and Clinitest result in insulin dependent diabetes mellitus. Lancet 1977; 2: 1156-1157.
9. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complication. Ann Intern Med 1984; 101: 527-535.
10. Kennedy L, Mehl TD, Riley WJ, Merimee TJ. Non-enzymatically glycosylated serum protein in diabetes mellitus: an index of short-term glycaemia. Diabetologia 1981; 21: 94-100.
11. Dronge AS, Perkal MF, Kancir S, Concato J, Aslan M, Rosenthal RA. Long-term glycemic control and postoperative infectious complications. Arch Surg 2006; 141: 375-380.
12. Kowalczuk A, Herdyńska-Wąs M, Foremny J, Przybylski R, Kucewicz E, Zembala M. Treatment of cardiac surgery in the elderly patients: a challenge, but also a test for treating. Cardiology Every Day 2010; 5: 90-92.
13. Zerr KJ, Furnary AP, Grunkemeier GL, Bookin S, Kanhere V, Starr A. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 1997; 63: 356-361.
14. Furnary AP, Gao G, Grunkemeier GL, Wu Y, Zerr KJ, Bookin SO, Floten HS, Starr A. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003; 125: 1007-10021.
Copyright: © 2016 Polish Society of Cardiothoracic Surgeons (Polskie Towarzystwo KardioTorakochirurgów) and the editors of the Polish Journal of Cardio-Thoracic Surgery (Kardiochirurgia i Torakochirurgia Polska). This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Liczba stron: 268
Intensywna terapia vademecum (redaktorzy: Tero Ala-Kokko, Juha Perttilä, Ville Pettilä, Esko Ruokonen)
Leki w intensywnej terapii (redaktorzy: Esko Ruokonen, Irma Koivula, Ilkka Parviainen, Juha Perttilä
Redaktorzy wydania polskiego: Andrzej Kański, Jan Adamski
Format: 132×210 mm
Liczba stron: 640
Ragavendra R. Baliga
redaktor wydania polskiego prof. nadzw. dr hab. Maciej Banach
Format: kieszonkowy 110 x 190
Liczba stron 92
pod redakcją Jacka Rysza i Macieja Banacha
Liczba stron: 268